Last10K.com

Aptevo Therapeutics Inc. (APVO) SEC Filing 10-Q Quarterly report for the period ending Tuesday, March 31, 2020

SEC Filings

APVO Quarterly Reports

Aptevo Therapeutics Inc.

CIK: 1671584 Ticker: APVO
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2020
May 13, 2020
Cover [Abstract]  
Document Type10-Q 
Amendment Flagfalse 
Document Period End DateMar. 31, 2020 
Document Fiscal Year Focus2020 
Document Fiscal Period FocusQ1 
Trading SymbolAPVO 
Entity Registrant NameAPTEVO THERAPEUTICS INC. 
Entity Central Index Key0001671584 
Current Fiscal Year End Date--12-31 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companytrue 
Entity Extended Transition Periodtrue 
Entity Shell Companyfalse 
Document Transition Reportfalse 
Document Quarterly Reporttrue 
Entity Interactive Data CurrentYes 
Entity Common Stock, Shares Outstanding 3,232,811
Title of 12(b) SecurityCommon Stock, $0.001 par value per share 
Security Exchange NameNASDAQ 
Entity Address, Address Line One2401 4th Avenue 
Entity Address, Address Line TwoSuite 1050 
Entity Address, City or TownSeattle 
Entity Address, State or ProvinceWA 
Entity Address, Postal Zip Code98121 
City Area Code206 
Local Phone Number838-0500 
Entity Incorporation, State or Country CodeDE 
Entity Current Reporting StatusYes 
Entity Tax Identification Number81-1567056 
Entity File Number001-37746 

View differences made from one quarter to another to evaluate Aptevo Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aptevo Therapeutics Inc..

Continue

Assess how Aptevo Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aptevo Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Product
Earnings
Shares
Debt
Other
Inside Aptevo Therapeutics Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Changes In Stockholders' Equity (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Cash, Cash Equivalents And Restricted Cash - Additional Information (Details)
Cash, Cash Equivalents And Restricted Cash - Schedule Of Cash, Cash Equivalents And Long-Term Restricted Cash (Details)
Cash, Cash Equivalents, And Restricted Cash
Cash, Cash Equivalents, And Restricted Cash (Tables)
Collaboration Agreements
Collaboration Agreements - Additional Information (Details)
Debt
Debt - Additional Information (Details)
Equity
Equity (Tables)
Equity - Additional Information (Details)
Equity - Assumptions Used In Valuing The Stock Options Granted Under Black-Scholes Valuation Model (Details)
Equity - Summary Of Restricted Stock Activity (Details)
Equity - Summary Of Stock Option Activity (Details)
Equity - Summary Of Stock-Based Compensation Expense Includes Amortization Of Stock Options And Restricted Stock Units Granted (Details)
Fair Value Measurements
Fair Value Measurements - Additional Information (Details)
Leases
Leases (Tables)
Leases - Additional Information (Details)
Leases - Components Of Lease Expense (Details)
Leases - Summary Of Right Of Use Assets Acquired Under Operating Leases (Details)
Nature Of Business And Significant Accounting Policies
Nature Of Business And Significant Accounting Policies (Policies)
Nature Of Business And Significant Accounting Policies - Additional Information (Details)
Net Income (Loss) Per Share
Net Income (Loss) Per Share (Tables)
Net Income (Loss) Per Share - Computation Of Basic And Diluted Net Loss Per Share (Details)
Net Income (Loss) Per Share - Summary Of Potentially Dilutive Shares Excluded From Calculation Of Net Loss Per Share (Details)
Reverse Stock Split
Reverse Stock Split - Additional Information (Details)
Sale Of Aptevo Biotherapeutics
Sale Of Aptevo Biotherapeutics (Tables)
Sale Of Aptevo Biotherapeutics - Additional Information (Details)
Sale Of Aptevo Biotherapeutics - Gain Of Sale Of Business (Details)
Sale Of Aptevo Biotherapeutics - Summary Of Reconciliation Of Carrying Amounts Of Assets And Liabilities And Income (Loss) From Discontinued Operation (Details)

Material Contracts, Statements, Certifications & more

Aptevo Therapeutics Inc. provided additional information to their SEC Filing as exhibits

Ticker: APVO
CIK: 1671584
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-20-025066
Submitted to the SEC: Wed May 13 2020 4:16:41 PM EST
Accepted by the SEC: Wed May 13 2020
Period: Tuesday, March 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/apvo/0001564590-20-025066.htm